Nanjing Apollomics Biotech Inc. located in the Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City, was founded by high-level overseas talents after returning home. The company is committed to developing domestic clinical detection reagents and disease detection services that match the world's leading mass spectrometry detection technology in line with the core corporate values of "customer orientation, teamwork, honesty, integrity, passion and creativity, and the spirit of ownership". The operation model integrates independent research and development, production synthesis, market sales, and testing services, with a complete industrial chain, mainly targeting the development of China's pharmaceutical, health, environmental protection, and other fields, with huge market potential.

The company's products include various Stable nuclide standards, medical diagnostic kits and supporting database systems. At present, a variety of Stable nuclide standards have been developed to fill the gap in China, including fat soluble vitamins, water-soluble vitamins, acyl carnitine, steroid hormones, etc. For example, the company has developed a new synthesis route for acylcarnitine, with the world's most complete series of deuterated acylcarnitine internal standards. The company's unique intellectual property rights of high-throughput molecular labeling technology directly benchmark similar products of a giant company in the United States. It has achieved a process from following, running in parallel, and then leading. Not only has it reduced customer costs, but it also has better performance, which can be widely applied in various fields such as scientific research, drug development, clinical testing, and so on. At the same time, the company is about to launch a full set of domestic vitamins, screening of rare metabolic genetic diseases of newborns and other clinical diagnostic kits (at different stages of registration application), and strive to provide customers with various products with advanced technology and high cost performance. The goal is to improve the level of molecular medical testing, as well as the efficiency and accuracy of disease detection in China, especially to promote the popularization and application of internationally advanced mass spectrometry detection technology in neonatal genetic disease screening and adult health testing.

The company has been recognized as a national high-tech enterprise and has obtained financing from renowned venture capital institutions. At the same time, it maintains close cooperation with many famous universities, listed companies, and tertiary hospitals both domestically and internationally.

Nanjing Apollomics is grateful to friends from all walks of life for their kindness to our company and for their sincere cooperation and solidarity in times of adversity. Our company sincerely welcomes new and old friends to visit, exchange and negotiate, and seek common development. We look forward to strong cooperation with our customers and working together to create a better tomorrow!